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REGULATING CLINICAL RESEARCH: INFORMED
CONSENT, PRIVACY, AND IRBS
SHARONA HOFFMAN

I. INTRODUCTION
During the past two decades, the United States has experienced
dramatic developments in the area of biomedical research. 1 Expanding
budgets, 2 augmented computer capabilities, and the Human Genome
Projece have all significantly enhanced research capabilities. 4
Consequently, the number of research projects conducted in this country is
ever growing, 5 and the enrollment of an adequate number of human
subjects is becoming an increasingly challenging task. 6 In the words of
one commentator, "never have so many human clinical trials been
underway and offered so much promise for improving human health . . .
[and] never have the economic and regulatory challenges been as great. 7"

Copyright © 2002, Sharona Hoffman
I
See Beverly Woodward; Challenges to Human Subject Protections in US Medical
Research, 282 JAMA 1947, 1948 (1999).
2
See Harold Y. Vanderpool, Introduction and Overview: Ethics, Historical Case
Studies, and the Research Enterprise, in THE ETHICS OF RESEARCH INVOLVING HUMAN
SUBJECTS: FACING THE 21 5T CENTURY 1,13(Harold Y. Vanderpool ed., 1996) (hereinafter
THE ETHICS OF RESEARCH] ("[F]unding for biomedical research from federal, state, local,
philanthropic, and industry sources had reached the amazing sum of $22.5 billion by
1990."); See also Gregg Easterbrook, What Went Right: Modest Gain, THE NEW REPUBLIC,
Jan. 22,2001, at 12, 15 (explaining that the National Institutes of Health's (NIH) budget
increased 111% during the Clinton presidency).
3
See Leroy Hood & Lee Rowen, Genes, Genomes and Society, in GENETIC
SECRETS: PROTECTING PRIVACY AND CONFIDENTIALITY IN THE GENETIC ERA 3 (Mark A.
Rothstein ed., 1997).
4
See Woodward, supra note 1, at 1948.
Elizabeth Austin, Flying Double-Blind Would You Be Willing to Risk Your Health
for Science? CHI. TRIB., Sept. 10, 2000, at 16, 18 ("An estimated 60,000 to 70,000
[clinical] trials are being conducted at any given time in the United, States.").
6
Id. See also, Kurt Eichenwald and Gina Kolata, Drug Trials Hide Conflicts for
Doctors, N.Y. TIMES, May 16, 1999, at I. The article attributes the proliferation of drug
trials in the 1990s to managed care and the restrictions it placed on drug prices. Id. Since
drug companies were limited in the prices they could charge for each drug, they opted to
increase the number of drugs they sold in order to maintain profitability. I d. Thus began the
industry's''rush to drug development." Id.
7
Michael J. Malinowski, Institutional Conflicts and Responsibilities in an Age of
Academic-Industry Alliances, 8 WIDENER L. SYMP. J. 47, 47 (2001) (citation omitted).
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Clinical research involving human participants is governed by federal
regulations that have bl'!en promulgated by the Department of Health and
Human Services (DHHS) and the Food and Drug Administration (FDA). 8
In light of the proliferation of medical research, however, an increasing
number of critics are voicing serious concerns about inadequate
enforcement of the regulations· and unacceptable research risks. 9 In recent
years, several subjects have died as a result of treatment received in
clinical trials and several well-publicized lawsuits have been filed against
researchers, research institutions, and institutional review boards (IRBs ). 10
The most prominent case is that of Jesse Gelsinger, an eighteen-year old
man with a rare metabolic disease, who died . while undergoing
experimental genetic therapr administered in a clinical study at the
University of Pennsylvania. 1 In addition, a healthy research volunteer
died as a res~lt of an experiment r_el~tin~ to asthma that was c?nd~cted at
Johns Hopkins School of Medtcme. 1 Two recent lawsmts mvolve
individuals who received an experimental melanoma vaccine in a clinical
trial conducted at the University of Oklahoma Health Science Center in
Tulsa 13 and patients who participated in blood cancer trials at the Fred

21 C.F.R. §§ 50.1-56.124 (2002); 45 C.F.R. §§ 46.101-46.409 (2001).
See Protecting Human Clinical Research Patients: Hearing on Institutional
Review Boards (IRBS) Before the House Comm. on Gov 't Reform & Oversight Subcomm.
on Human Resources, 105'h Cong. (1998) (statement of George Grob, Deputy Inspector
General for Evaluation and Inspections, Department of Health and Human Resources),
available at 1998 WL 12761511 (hereinafter 1998 Hearing).
10
IRBs are committees designated by research institutions to review, approve, and
periodically monitor biomedical research studies. 21 C.F.R § 56.102(g) (2002); See also 45
C.F.R. § 46.102(g)(2001).
11
Rick Weiss & Deborah Nelson, Teen Dies Undergoing Experimental Gene
Therapy, WASH. PosT, Sept. 29, 1999, at AI; Gelsinger v. Trustees of the Univ. of
Pennsylvania, No. 000901885 (Philadelphia County Ct. Com. Pl.) (filed Sept. 18, 2000).
The lawsuit was settled on Nov. 3, 2000 and the details of the agreement were not released.
See Alison Schneider, U. of Pennsylvania Settles Lawsuit Over Gene-Therapy Death,
CHRON. HIGHER Eouc., Nov. 6, 2000, available at htip:/lchronicle.comldailyl
2001/ll/2000//0602n.htm..
12
Robert Steinbrook, Protecting Research Subjects - The Crisis at Johns Hopkins,
346 N. ENGL. J. MED. 716-720 (2002). In the study, subjects were instructed to inhale a
drug called hexamethonium that causes airways to constrict, and physicians observed the
subject's airways as they took deep breaths. !d. at 717.
13
Robertson v. McGee, No. 4:01-CV-60 (N.D. Okla.) (filed Jan. 29, 2001). The
plaintiffs seek damages arising from alleged failures to comply with the federal regulations
that govern biomedical research. Id
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14

Hutchinson Cancer Research Center in Seattle.
Intensifying concerns
about both human subject welfare and potential liability are stimulating
urgent calls for regulatory reforms.
Part I of this Article provides a brief historical overview of Twentieth
Century research abuses and the development of regulatory oversight in the
United States. Part II discusses informed consent, IRBs, and the
regulations that govern them. Part III analyzes contemporary deficiencies
in the regulatory system. Finally, Part IV offers recommendations for
reform.

II. A HISTORICAL OVERVIEW OF RESEARCH ABUSES AND THE
DEVELOPMENT OF RESEARCH REGULATIONS

During World War II, the Nazis conducted large-scale, experiments on
concentration camp prisoners that were designed not . only to gather
medical data, but also to torture and kill the subjects. In some camps,
German doctors infected numerous healthy inmates with yellow fever,
smallpox, ~bus, cholera, and diphtheria germs that caused hundreds of
them to die. 5 In other camps Nazi physicians conducted experiments
relating to high altitude, malaria, fret)zing, mustard fflas, bone
transplantation, sea water, sterilization, and incendiary bombs. The full
scope and ghastliness of the Nazi medical experimentation was revealed
and documented during the Nuremberg Trials after World War II. 17
In the United States, medical research was conducted for many
decades without any regulatory oversight. 18 Perhaps not surprisingly, in an
environment devoid of regulation and monitoring, an alarming number of

14

Wright v. Fred Hutchinson Cancer Research Ctr, No. 01-2-008376 (Kitsap
County Sup. Ct. filed Mar. 29, 2001). The complaint alleges that subjects were not fully
informed of the study's risks, and that the investigators were unduly influenced by the
allure of potential financial profits. Jd. Eighty of the eighty-two individuals who
participated in the trial between 1981 and 1993 died. Jd.; Vida Foubister, Lawsuits have
doctors wary, but not quitting research yet, 44 AM. MED. NEWS, Apr. 16,2001, at 1-2.
15
ALLEN M. HORNBLUM, ACRES OF SKIN: HUMAN EXPERIMENTS AT HOLMSBURG
PRISON 75 (1998).
16
ld. at 75-77.
17
The Nuremberg Trials commenced on November 20, 1945 at the Palace of Justice
in Nuremberg, Germany. Fifteen of the twenty-three defendants were found guilty of"war
crimes and crimes against humanitY," and seven of them were sentenced to death. See
Alexander Mitscherlich & Fred Mielke, Epilogue: Seven Were Hanged, in THE NAZI
DOCTORS AND THE NUREMBERG CODE 105-06; Bernard Meltzer, \'War Crimes": The
Nuremberg Trial and the Tribunal for the Former Yugoslavia, 30 VAL. L. REv. 895, 896
(1996).
18
Vanderpool, supra note 2, at 8.
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19

research abuses occurred in this country as well. In the early 1950s,
nearly one hundred percent of participants in Phase I clinical trials, the first
and riskiest phase of human research studies/0 were prisoners? 1 In Ohio,
for examJ:>le, live cancer cells were introduced into both forearms of many
prisoners. 22 Two weeks after the injection, the affected area of one arm
would be surgically removed for study, while the malignant cells were left
in the other forearm for further observation. 23 At the Ionia State Hospital
in Michigan, at least 142 inmates were recruited for secret CIA
psychological experiments. 24 As late as 1969, eighty-five percent of new
medications were still tested on prisoners. 25
Research abuses in the decades following WWII were not limited to
the prison environment but also involved other vulnerable populations. 26
For example, patients at the Jewish Chronic Disease Hospital in Brooklyn
had live cancer cells injected under their skin, and retarded children in the
Willowbrook State School on Staten Island were infected with a mild
strain of hepatitis. 27 The experiments were done without the subjects'
knowledge or consent. 28
.
In 1972, news of the notorious Tuskegee syphilis study highlighted the
problem of mistreatment of medical research subjects in the United
States. 29 The Tuskegee study, whose participants were all AfricanAmerican men, was conducted from 1932 until the beginning of the 1970s
and sought to analyze the natural progression of untreated syphilis. 30 The
researchers, therefore, did not provide patients with penicillin, an antibiotic
that is a fully effective cure for syphilis and was widely available as early

19

I d.
See 21 C.F.R. § 312.21(a) (2002). Human research studies are often called
"clinical trials." !d.
21
HORNBLUM, supra note 15, at 43.
22
HORNBLUM, supra note 15, at 93.
23
HORNBLUM, supra note 15, at 93.
24
HORNBLUM, supra note 15, at 95. ,
25
Kathleen Schroeder, A Recommendation to the FDA Concerning Drug Research
on Prisoner, 56 S. CAL. L. REv. 969, 971 (1983).
26
Henry K. Beecher, Ethics and Clinical Research, 274 NEW ENG. J. MED. 1354,
20

1354-60 (1966).
27
!d. at 1358; Vanderpool, supra note 2, at 9.
28
Vanderpool, supra note 2, at 9.
29
See Colleen M. McCarthy, Note, Experimentation on Prisoners: The Inadequacy
of Voluntary Consent, 15 NEW ENG. J. ON CRIM. & Clv. CONFINEMENT 55, 58 (1989); See
also Vanderpool, supra note 2, at 9. The first report of the study appeared in a July 1972
article by Jean Heller entitled Syphilis Victims in US. Study Went Untreated for 40 Years.
30
WILLIAM J. CURRAN ET AL., HEALTH CARE LAW AND ETHICS 276 (5th ed. 1998).
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as 1953. The subjects, who believed they were receiving adequate care,
continued to suffer unnecessarily from the debilitating effects of the
disease. 32
The federal government finally responded to publicity concerning
research abuses by promulgating oversight regulations. The FDA and the
National Institutes ofHealth (NIH) developed internal policy guidelines in
1966 and 1971, respectively, and these became federal regulations in
33
1974. The National Commission for the Protection of Human Subjects in
Biomedical and Behavioral Research was established through the National
34
Research Act of 1974 and operated for four years, until 1978.35 Pursuant
to the Commission's recommendations; the federal regulations underwent
revision in 1981, and they have remained in effect since then. 36
III. THE FEDERAL REGULATIONS THAT GOVERN IRBs AND
INFORMED CONSENT

A. What Is Regulated?
Research studies, generally termed "clinical trials," for the
development of new drugs and devices are regulated by the FDA. 37
Medications that are the focus of study in clinical trials are called
investigational new drugs (INDs). 38 Clinical trials that involve treatments

31.

!d.; Vanderpool, supra note 2, at 9.
CURRAN ET AL., supra note 30, at 276.
33
Vanderpool, supra note 2, at 10.
34
See National Research Service Award Act of 1974, Pub. L. 93-348, 88 Stat. 342 §
201; McCarthy, supra note 29, at 58-59.
35
BARUCH A. BRODY, ETHICAL ISSUES IN DRUG TESTING, APPROVAL AND PllJCING
103 (1995).
36
Vanderpool, supra note 2, at 10.
37
21 C.F.R. § 7.3(t) (2002) ("Product" m\!anS an article subject to the jurisdiction of
the Food and Drug Administration, including any food, drug, and device intended for
human or animal use ....)
38
21 C.F.R. § 312.23(a) (2002). Medical research for drugs is conducted in three or
four phases of clinical trials. See generally§ 312.23. In Phase I, the new drug or treatment
is given to patients or healthy individuals to determine its toxicity, most effective method of
administration, and safe dosage range. !d. Participants in the trial receive increasing
dosages of the substance in order to determine its metabolism, absorption, and side effects
and to gain early evidence of its effectiveness, if possible. Id. Phase I clinical trials
generally involve only 20 to 80 subjects, last about a year, and have a very high failure rate.
Seventy percent of drugs submitted for Phase I clinical trials fail to progress to Phase II. See
Veronica Henry, Problems with Pharmaceutical Regulations In the United States, 14 J.
LEGALMED. 617 (1993).
(continued)
32
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other than drugs and devices, such as surgery or bone marrow transplants,
are not regulated by the FDA and are subject to DHHS regulation only if
they are "conducted, supported or otherwise subject to regulation by any
federal department or agency .... " 39
B. IRBs

Research that is conducted, supported, or regulated by DHHS, the
FDA, or another federal agency must be reviewed by an IRB. 40 An IRB is
a committee designated by an institution to provide initial approval and
periodic monitoring for biomedical research studies. 41 The IRB's primary
purpose is to protect the rights and welfare of human subjects. 42 The IRB
reviews a document known as the "protocol" for each proposed clinical
trial, which describes the objectives of the research, its procedures,
eligibility requirements for participants, the number of subjects to be
tested, and other details. 43 The material submitted to the IRB also includes
a document known as the "informed consent" form, which is given to all
potential enrollees in order to provide them with a detailed explanation of
the clinical trial and an opportunity to agree to participation in the study. 44
Phase H trials are designed to determine the effectiveness of the therapy. /d. The
treatment is administered to patients suffering from the condition for which the therapy is
intended. The trial often involves I 00 to 300 people and lasts about two years. /d.
Approximately 33% of drugs submitted for clinical trials fail in Phase II testing. /d.
Phase III clinical trials are conducted only after the treatment has proven effective
through Phase I and II trials. /d. The third phase attempts to assess the medical results of the
experimental therapy in comparison with standard therapy or no therapy at all. /d. Phase Ill
studies usually involve several hundred to several thousand patients and last about three
years. /d.
The FDA may also require post marketing or Phase IV clinical trials. /d. These studies
are designed to determine the existence of less common adverse reactions, the effect of the
drug on morbidity or mortality, or the effect of the drug on a particular patient population,
such as children. See 21 C.F.R. §§ 312.21, 312.85 (2002); See also Veronica Henry,
Problems with Pharmaceutical Regulation in the United States, 14 J. LEGAL MED. 617,
621-22 (1993).
39
45 C.F.R. § 46.101(a) (2001); See also Richard S. Saver, Note, Reimbursing
New Technologies: Why Are the Courts Judging Experimental Medicine?, 44 STAN. L.
REv. 1095, 1110-11 (1992); Norman Daniels & James E. Sabin, Last Chance Therapies and
Managed Care: Pluralism, Fair Procedures, and Legitimacy, HASTINGS CENTER REPORT,
Mar.-Apr. 1998, at 29.
40
21 C.F.R. §§ 56.101(a), 56.103 (2002); 45 C.F.R. § 46.101(a) (2001).
41
21 C.F.R § 56.102(g) (2002); 45 C.F.R. § 46.102(g) (2001).
42
21 C.F.R. § 56.102(g) (2002).
43
21 C.F.R § 56.115 (a) (2) (2002); 45 C.F.R. § 46.115 (a) (I) (2001).
44
21 C.F.R. § 50.20 (2002); 45 C.F.R. § 46.116 (2001).
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After the IRB approves the informed consent form, all those who wish to
become human subjects must sign a copy of the document, affirming the
voluntariness oftheir choice.45
The structure and duties of IRBs are governed by the DHHS and FDA
regulations. 46 Each IRB must be composed of at least five members with
diverse cultural and ethnic backgrounds, and both men and women should
be included. 47 At least one member of the IRB should be a person whose
principal concerns are in the scientific realm, and one individual's
expertise should be nonscientific (e.g. a lawyer or minister). 48
Furthermore, to enhance its objectivity, each IRB must include at least one
member who is not otherwise affiliated with the research facility and who
has no immediate family members affiliated with the entity. 49 According to
DHHS's Office for Protection from Research Risks (OPRR), now renamed
the Office for Human Research Protection (OHRP), eighty-six percent of
IRB members in 1995 were affiliated with academic research institutions
as full-time faculty (56%), clinical and research staff (18%), and
administrators (6%). 50 Academic institutions do not compensate IRB
members for their work, and thus these individuals must volunteer their
time without receiving payment or relief from other job duties. 5 1
Unless an expedited review is conducted, research protocols must be
reviewed at IRB meetings at which a majority of members are present,
Decisions
including a member whose expertise is nonscientific. 52
concerning approval of each study are made by majority vote. 53
The IRB may approve, disapprove, or require modifications to the
proposed research activities. 54 Investigators must be given written
notification of the IRB's decisions, and IRBs are required to monitor the
clinical trials they approve at intervals of at least once a year, or more

45

21 C.F.R. § 56.111(a)(4) (2002); 45 C.F.R. § 46.111(a)(4) (2001).
21 C.F.R. §56 101 (a) (2002); 45 C.F.R § 46.101 (a) (2001).
47
21 C.F.R. § 56.107(a) (2002); 45 C.F.R. § 46.l07(a)-(b) (2001).
48
21 C.F.R. § 56.107(c) (2002); 45 C.F.R. § 46.l07(c) (2001).
49
21 C.F.R. § 56.107(d) (2002); 45 C.F.R. § 46.107(d) (2001).
50
JAMES BELL et al., EVALUATION OF NIH IMPLEMENTATION OF SECTION 491
OF THE PUBLIC HEALTH ACT, MANDATING A PROGRAM OF PROTECTION FOR
RESEARCH SUBJECTS, FINAL REPORT 17 ( 1998).
51
Kerry Burke, Loose-Fitting Genes: The Inadequacies in Federal Regulation of
Institutional Review Boards, 3 B.U. J. SCI. & TECH. L. 10, 38 (1997).
52
21 C.F.R. § 56.108(c) (2002); 45 C.F.R. § 46.108(b) (2001).
53
21 C.F.R. § 56.l08(c) (2002); 45 C.F.R. § 46.l08(b) (2001).
54
21 C.F.R. § 56.l09(a) (2002); 45 C.F.R. § 46.109(a) (2001).
46
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frequently, depending on the severityofthe risks entailed.ss This periodic
monitoring is known as "continuing review." 56
Before approving a clinical trial, the IRB must ensure that· specific
criteria are met. These include: (1) risks to participants are minimized; (2)
risks to subjects are reasonable in light of anticipated benefits; and (3)
selection of participants is equitable, and the protocol is sensitive to the
particularized problems of research involving vitlnerable populations, such
as children, prisoners, pregnant women, mentaHr disabled individuals, or
economically or educationally deprived persons. 5
C. Informed Consent

The contents of informed consent forms are also govffrned by the
federal regulations. The informed consent document must be written in
language that is accessible to subjects. 58 Informed consent may not include
language that waives any of the subject's rights or releases the institution
or research personnel from liability for negligence. 59 The regulations
further require that informed consent be obtained in writing from each
enrollee, though they allow for certain exceptions. 60
The regulations specify certain data that must be featured on the
informed consent document. This information includes a description of the
research, an explanation of risks, benefits, and alternatives, a discussion of
confidentiality, a list of contact people, and· a statement that participation is
voluntary and may be discontinued at any time. 61
55

21 C.F.R. § 56.109(e)-(t) (2002); 45 C.F.R. § 46.109(d)-(e) (2001).
21 C.F.R. § 56.109(t) (2002); 45 C.F.R. § 46.109(e) (2001).
57
21 C.F.R. § 56.11l(a) (2002); 45 C.F.R. § 46.11l(a) (2001).
58
21 C.F.R. § 50.20 (2002); 45 C.F.R. § 46.116 (2001).
59
21 C.F.R. § 50.20 (2002); 45 C.F.R. § 46.116 (2001).
60
21 C.F.R. § 50.27 (2002); 45 C.F.R. § 46.117 (2001).
61
21 C.F.R. § 50.25(a) and (b) (2002); 45 C.F.R. § 46.116(a) and (b) (2001). The
provisions read as follows:
(a) Basic elements of informef:l consent. [I]n seeking informed consent the following
information shall be provided to each subject:
(I) A statement that the study involves research, an explanation of the purposes of the
research and the expected duration of the subject's participation, a description of the
procedures to be followed, and identification of any procedures which are experimental;
(2) A description of any reasonably foreseeable risks or discomforts to the subject; A
description of any benefits to the subject or to others which may reasonably be expected
from the research;
(3) A disclosure of appropriate alternative procedures or courses of treatment, if any,
that might be advantageous to the subject;
(4) A statement describing the extent, if any, to which confidentiality of records
identifying the subject will be maintained;
(continued)
56
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D. Research Involving Only Existing Medical Records Or Tissue Samples
In some cases investigators conduct research that does not involve
treatment of any human subject. Instead, the research entails the study of
existing medical records or tissue sai11ples. 62 For example, researchers
might want to determine whether patients who have .a particular type of
cancer suffered certain symptoms before their diagnosis and might attempt
to make that determination through an examination of their recorded
medical histories. Investigators are not required to obtain informed
consent from subjects for such research if the information is publicly
available or if the researcher will record the data in a way that will make it
impossible for subjects to be identified. 63
In addition, the regulations provide that an IRB may waive informed
consent requirements if it finds "[t]hat the research presents no more than

(5) For research involving more than minimal risk, an explanation as to whether any
compensation and an explanation as to whether any medical treaJments are available if
injury occurs and, if so, what they consist of or where further information may be
obtained;
(6) An explanation of whom to contact for answers to pertinent questions about the
research and research subjects' rights, and whom to contact in the event of a researchrelated injury to the subject; and
(7) A statement that participation is voluntary, refusal to participate will involve no
penalty or loss of benefits to which the subject is otherwise entitled, ;md the subject
may discontinue participation at any time without penalty or Joss of benefits to which
the subject is otherwise entitled.
(b) Additional elements of informed consent. When appropriate, one or more of the
following elements of information shall also be provided to each subject:
(I) A statement that the particular treatment or procedure may involve risks to the
subject (or to the embryo or fews, if the subject is or may become pregnant) which are
currently unforeseeable;
(2) Anticipated circumstances under which the subject's participation may be
terminated by the investigator without regard to the subject's consent;
(3) Any additional costs to the subject that may result from participation in the
research;
(4) The consequences of a subject's decision to withdraw from the research and
procedures for orderly termination of participation by the subject;
(5) A statement that significant new finding developed during the course of the
research which may relate to the subject's willingness to continue participation will be
provided to the subject; and
(6) The approximate number of subjects involved in the study.
45 C.F.R. § 46.116(a) and (b) (2001).
62
45 C.F.R. § 46.101 (b)(4) (2001).
63

Jd.
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minimal risk of harm to subjects and involves no procedures for which
written consent is normally required outside of the research context. " 64
Accordingly, in limited circumstances in which subject welfare will not be
compromised, this provision could allow for the use of identifiable medical
records without subject consent. 65
IV. DEFICIENCIES IN THE REGULATORY SYSTEM

A. IRB Workloads

A 1998 statement issued by the Office of Inspector General of the U.S.
Department of Health and Human Services (OIG) was highly critical of
contemporary research oversight. 66 The OIG stated that the enormous
workloads of many IRBs currently prevent them from adequately
performing their review functions. A follow-up report issued by the Office
of Inspector General in April of 2000 concluded that in the intervening two
years, only minimal progress had been made to diminish the workload
pressures of IRBs. 67 The number of initial reviews conducted by IRBs
increased by an average of forty-two percent from 1993 to 1998, and some
IRBs review up to 2,000 protocols per year. 68 Some IRBs also receive
200 or more reports of adverse events each month concerning the clinical
trials they oversee. 69 An external review conducted at Johns Hopkins
University after the death of a healthy human subject revealed that until
June of 2001 a single IRB, meeting every two weeks, was responsible for
the approval of 800 new protocols and the annual reviews they generated. 70
The reviewers emphatically stated:
"[w]e view this as grossly
64

45 C.F.R. § 46.117(c)(2) (2001).
45 C.F.R. Pts. 160, 164; Jennifer Kulynych & David Korn, The Effect of the New
Federal Medical-Privacy Rule on Research, 346 N. ENGL. J. MED. 201, 201-04 (2002)
(discussing new privacy rule that became effective on Apr. 14, 2001. Most health care
providers will be required to'~omply with the new rule by Apr. 2003); See also Standards
65

for

Privacy

of

Individually

Identifiable

Health

Information,

available

at

http://www.hhs.gov/ocr/hipaalfinalmaster.html (last visited July 9, 2001). The use and
disclosure of protected health information is addressed in 45 C.F.R. §§ 164.501, 164.508(f),
and 164.512(i).
66
See 1998 Hearing, supra note 9.
67
Protecting Human Research Subjects: Status ofRecommendations (2000) (Office
of [nspector General, Department of Health and Human Services), available at 2000 WL
553517, at *3.
68
!d. at *5. The average local lRB meeting was found to last approximately 2.5
hours and to include 18 initial reviews, 9 expedited reviews, 43 amendments to protocols
and 21 adverse-event reports. !d. at *6.
69
!d.
70

Steinbrook, supra note 12, at 719.
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inadequate." As noted above, most IRB members have full time jobs on
the faculties or staffs of research institutions, 72 and are not paid for their
IRB services or relieved of other work duties. 73 Consequently, the time
members can spend on IRB work is limited, and IRBs generally meet only
·
once or twice a month for a few hours. 74
OPRR expressed concern that the IRBs' work is also hampered by
deficient expertise and resources. 75 Some IRB members lack in-depth
understanding of the federal regulations governing biomedical research,
and IRBs do not have the space, privacy, and level of staff support
necessary to perform their duties adequately. 76 Small IRBs may have only
one salaried staff member to coordinate all IRB activities and perform
administrative tasks. 77
If IRBs become frequent defendants in lawsuits, 78 the IRB system may
be fundamentally threatened. Since IRBs rely heavily on the work of
volunteers, they may find it difficult to recruit members in the future.
Physicians who are concerned about potential liability may be very
reluctant to offer their services to IRBs. 79
B. Flaws In The Informed Consent Process
An increasing volume of evidence indicates that the informed consent
process is severely flawed in many cases. Often, human subjects either
are given insufficient information or do not comprehend the data they
receive.
The 1998 OIG statement was very critical of informed consent
procedures. 80 It noted, for example, that a 1995 Advisory Commission on
71

Steinbrook, supra note 12, at 719.
See BELL, supra note 50 and accompanying text.
73
Steinbrook, supra note 12, at 717; Burke, supra note 51, at 38.
74
Steinbrook, supra note 12, at 719.
75
U.S. DEP'T OF HEALTH & HUMAN SERVS., OFFICE FOR HUMAN RESEARCH PROTS.,
OHRP COMPLIANCE ACT!VlTIES: COMMON FINDINGS AND GUIDANCE (Sept. I, 2000),
available at http://ohrp.osophs.dhhs.gov/references/findings.pdf. [hereinafter OHRP].
76
ld.
72

77
78

1998 Hearing, supra note 9.
See e.g., Robertson v. McGee, No. 4:01-CV- 60 (N.D. Okla.) (filed Jan. 29,

2001).
79

Alan Milstein, an attorney who has filed several lawsuits against physician
investigators on behalf of clinical trial participants, has publiciy criticized IRBs as sharing
the blame for alleged injuries to human subjects. In one article he stated that "[I]n our
major institutions, where you've got Nobel scientists and Nobel doctors and well-regarded
professors, the IRBs more or less simply rubber-stamp whatever protocol one of these men
put before them." Foubister, supra note 14, at I.
80
See 1998 Hearing, supra note 9.
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Human Radiation Experiments found, after interviewing actual subjects
that few realized they were involved in research, and many had little
understanding of the informed consent forms they had signed. 81
Commonly; the problem is confusion about the differences between
research and clinical treatment. 82 While some research subjects are healthy
volunteers who would not otherwise seek medical treatment, many are
patients with particular illnesses who are recruited for cliniCal research by
their treating physicians. These patients are vulnerable to a phenomenon
known as the "therapeutic misconception. " 83 Because they are sick and are
recruited for enrollment by their doctors, they become convinced that their
research participation will be of definite medical benefit to them. These
patients are therefore resistant to explanations that treatments involved in
clinical trials are unproven and experimental, no matter how clearly and
explicitly these explanations are given.
Numerous studies have focused on the issue of informed consent and
have revealed very troubling evidence concerning the ability of research
subjects toprovide valid consent. 84 In a labor-induction study with fiftytwo participants, thirty-nine percent of the women were found to be
unaware that they were participating in a research study although all had
81

See 1998 Hearing, supra note 9.
CHARLES LIDZ ET AL., INFORMED CONSENT: A STUDY OF DECISIONMAKING IN
PSYCHIATRY 28 (1984); See also Paul S. Appelbaum et al., False Hopes and Best Data:
Consent to Research and the Therapeutic Misconception, 17 HASTINGS CENTER REP. 20
(1987). The authors explain the problem as follows:
82

Most people have been socialized to believe that physicians (at least
ethical ones) always provide personal care. It may therefore be very
difficult, perhaps nearly impossible, to persuade subjects that this
encounter is different, particularly if the researcher is also the treating
physician, who has previously satisfied the subject's ·expectations of
personal care. Further, insofar as much clinical research involves
persons who are acutely ill and in some distress, the well-known
tendency of patients to regress and entrust their well-being to an
authority figure would undercut any effort to dispel the therapeutic
misconception.

!d.
83

Evan G. DeRenzo et al., Assessment of Capacity to Give Consent to Research
Participation: State-of-the-Art and Beyond, I J. HEALTH CAREL. & POL'Y 66, 72 (1998);
See also Holly A. Taylor, Barriers to Informed Consent, 15 SEMINARS IN ONCOL. NuRS. 89,
91 (1999) (noting that oncology patients often perceive enrollment in a research protocol as
their last chance to receive effective treatment).
84
DeRenzo, supra note 83, at 69; Janet Fleetwood, Conflicts of Interest in Clinical
Research: Advocating/or Patient-Subjects, 8 WIDENERL. SYMP. J 105, 108 (2001).
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85

signed informed consent forms.
Even those who realized they were
research subjects often misunderstood essential aspects of the study and
their role in it. 86
Several investigators asked fifty cancer patients to review a
hypothetical consent form for participation in a placebo-controlled clinical
trial. 87 Subjects were asked to interpret four different statements in the
consent form. 88 Depending on the statement, the subjects provided
incorrect answers twenty-six to fifty-four percent of the time. 89
In another survey, forty-seven percent of responding researchers
indicated that they thought few of their subjects, enrolled in multinational
studies in the 1980s, knew they wete participating in controlled
experiments, even though they had given written consent. 90 In two
additional studies, over three quarters of physicians who were questioned
believed that subjects rarely understood all the data given to them. 91
The difficulty of obtaining informed consent is exacerbated by the fact
that informed consent documents are generally written in language that is
technical and sophisticated and consequently inappropriate for the intended
audience. 92 While many informed consent document require a college
85

Bradford H. Gray, Complexities of Informed Consent, 437 ANNALS AM. ACAD.
PoL. & Soc. Sci. 37, 43 (1978). Gray states that the women's misunderstanding is
attributable to several factors "including the generally low educational levels of the unaware
subjects, the investigator's delegation to subordinates of the task of obtaining consent,
seeking consent in the labor room, and providing little oral explanation - sign this and we
can get started." Id.
86
BRADFORD H. GRAY, HUMAN SUBJECTS IN MEDICAL EXPERJMENTATION 103
(1975); See also Angela Estey et al., Are Research Subjects Able to Retain the Information
They Are Given During the Consent Process?, 3 HEALTH L. REv. 37 (1994). A study of29
subjects from two clinical trials at the University of Alberta Hospitals revealed that 14 of
them were unable to describe acclirately the type of research study in which they were
enrolled and 17 could not list any risks associated with participation in the trial although
risks had been explicitly explained to them. Id. at 40.
87
H. J. Sutherfand et al., Are We Getting Informed Consent for Patients with
Cancer?, 83 J. R. Soc. MED. 439 (1990).
88
I d. at 440.
89
Jd. at 441.
90
Sarah J.L. Edwards et al., The Ethics of Randomized Controlled Trials from the
Perspectives of Patients, the Public, and Healthcare Professionals, 317 BRJT. MED. J. 1209,
1209 (1998).
91
Id. at 1209-10.
92
Jay Katz, Human Experimentation and Human Rights, 38 ST. LoUis U. L.J. 7, 36
(1993); See also Christopher Daugherty et al., Perceptions of Cancer Patients and Their
Physicians Involved in Phase I Trials, 13 J. CLIN. ONCOL. 1062, 1065 (1995); Daugherty
found that the cancer patients' educational levels significantly influenced their ability to
·
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93

level reading comprehension ability, the average American has only an
eighth grade reading comprehension level. 94 Rather than providing useful
explanations for patients, the forms often serve to educate only the
medically trained IRB members who review them; 95
The challenge of obtaining genuine consent from subjects has had
grave consequences for some institutions. During 1998 and 1999, OPRR
suspended federal research funding at Chicago's Rush-Presbyterian-St.
Luke's Medical Center, the West Los Angeles VA Medical Center, Duke
University Medical Center, the University of Illinois at Chicago, and six
Universi~ of Colorado institutions, all ofwhich are well-regarded research
facilities. 6 In January of 2000, research activities were suspended at the
University of Pennsylvania and the University of Alabama at
Birmingham. 97 Prominent among the violations for which these entities
recall correctly the purpose of the phase I trials for which they were eligible to enroll.
While 71% of college educated patients were able to state the purpose of phase 1 trials, only
20% of those without a college degree could do so. Similarly, Casselith discovered that
patients with less than a high school education had difficulty remembering information
about a research protocol in which they had just consented to participate . Id Barrie R.
Cassileth et al., Informed Consent- Why Are Its Goals Impelfectly Realized?, 301 N. ENGL.
J. MED. 896, 898 {1980).
93
Holly Taylor, supra note 83, at 93 (noting that "the average consent form is
written at a level that requires at least a high school education or higher"); Henry W.
Riecken & Ruth Ravich, Informed Consent to Biomedical Research in Veterans
Administration Hospitals, 248 JAMA 344, 346 (1982) (noting that "most of the consent
forms are written in language that requires reading ability at the college level for
comprehension of the investigator's purpose," and that only 27% of VA patients surveyed
"had more than a high school education.").
94
Terry C. Davis et al., Reading Ability ofParents Compared with Reading Level of
Pediatric Patient Education Materials, 93 PEDIATRICS 460, 461-62 (1994); Stuart A.
Grossman et al., Are Informed Consent Forms Thai Describe Clinical Oncology Research
Protocols Readable By Most Patients and Their Families?, 12 J. CLIN. ONCOL. 2211, 2212
(1994).
95
See Davis, supra note 94; Grossman, supra note 94.
96
Vida Foubister, More Centers Cited for Ethics Lapses in Research, AM. MED.
NEWS, Nov. 1, 1999, at 8, 10; See also AMERICAN ASSOCIATION FOR THEADVANCEMENTOF
SCIENCE, PROFESSIONAL ETHICS, Summer 1999, at 3 (noting that OPRR shut down 1,000
human research studies at the University of Illinois at Chicago and investigated the
University of South Florida's IRB).
97
Marlene CimOQS, FDA cites violations, halts human gene therapy work at Penn,
THE PLAIN DEALER, Jan. 22, 2000, at 12A; Jay Reeves, Order suspends university's
medical research, THE PLAIN DEALER, Jan. 22, 2000, at 12A (reporting that the government
suspended about 25% of research studies conducted at the University of Alabama at
Birmingham).

2002]

REGULATING CLINICAL RESEARCH

85

were cited was the failure to obtain adequate informed consent from
subjects. 98
B. Informed Consent Is Particularly Difficult To Obtain From Gravely Ill
Patients
Genuine informed consent is particularly difficult to obtain when the
patients at issue suffer from life-threatening diseases. 99 The decisionmaking capacity of gravely ill patients is often compromised by the
emotional trauma of their illnesses or by various social and familial
pressures. Consequently, those who have the most to gain or lose from
receiving experimental treatment are also those who are least able to
provide meaningful informed consent.
Illness can be viewed as an "ontological assault" that undermines the
patient's identity by "attacking the fundamental unity of mind and
body." 100 A patient suffering from multiple sclerosis described the
experience of disease in these words:
The most deeply held assumption of daily life is the
assumption that I, personally, will continue to be alive and
it is in light of this assumption that one engages in daily
activities. The onset of illness, however, brings one
concretely face-to-face with personal vulnerability ....
Thus, the person who is ill . . . is unable readily to fit
illness into the typified schema used to organize and
interpret experience .... One finds oneself preoccupied with
the demands of the here and now, confined to the present
moment, unable effectively to project into the future. 101
Commentators have noted that serious sickness creates in patients a
strong desire to be cared for and to be free of the responsibility and stress
of decision-making, as though they were once again children. 102 Many
scholars have noted that the thought processes of those suffering from
prolonged or serious illnesses are often impaired and have urged that
rese~ch f:rotoc~ls involving such patients be subject to h~ightened IRB
scrutmy. 1 3 One mformed consent study found that as the senousness of the
98

Foubister, supra note 96, at 8, 10; Cimons, supra note 97, at 12-A; See also
OHRP, supra note 75.
99
Fleetwood, supra note 84, at l 07.
100
MARK A. HALL, MAKING MEDICAL SPENDING DECISIONS 36 ( 1997).
101
Id. at 28.
102
Id.
103
Alison Wichman, Protecting Vulnerable Research Subjects: Practical Realities
of Institutional Review Board Review and Approval, I J. HEALTH CAREL. & PoL'Y 88, 93
(1998) ("People suffering from prolonged or serious illnesses that are refractory to standard
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illness increases, the ability of potential subjects to remember information
relevant to their research participation decreases. 104 Seriously ill patients
may experience depression, extreme anxiety, rage, denial, or desperation to
find a cure, all of which may cloud their judgment and hamper their ability
to evaluate the benefits and risks of a clinical trial. 105

therapies, or for which there are no standard therapies, should be considered vulnerable
particularly when they are willing to take ahy risk for even a remote possibility of relief.");
DeRenzo et al., supra note 83, at 69, 78 ("(T]he majority of studies conclude that seriously
ill research subjects have difficulties in many facets of providing ethically valid consent,"
and "Serious disease produces desperation .... [b]oth on the part of subjects and their
families (that] can make persons vulnerable to manipulation"); George J. Annas, The
Changing Landscape of Human Exp~rimentation: Nuremberg, Helsinki, and Beyond, 2
HEALTH MATRIX 119, 134 (1992)("Terminally ill AIDS and cancer patients can be harmed,
misused, and exploited"); D. Christian Addicott, Regulating Research on the Terminally Ill:
A Proposal for Heightened Safeguards, 15 1. CONTEMP. HEALTH L. & PoL'Y 479, 493
( 1999) ("(T]he terminally ill share a number of relevant characteristics with the vulnerable
populations listed in the regulations, [and thus] an IRB would be well within its authority to
treat the terminally ill as vulnerable"); Sarah Hewlett, Consent to Clinical Research Adequately Voluntary or Substantially Influenced?, 22 J. MED. ETHICS 232, 233 (1996)
(noting that patients dealing with illness may experience a reduction in their autonomy due
to a variety of factors related to the physiologic and psychological impact of illness).
104
Monica H. Schaeffer et al., The Impact of Disease Severity on the Informed
Consent Process in Clinical Research, 100 AM. J. MED. 261, 264 (1996). The study
involved 127 subjects who were recruited from four different research protocols at the
National Institute of Health. /d. Nine subjects had metastatic cancer for which all treatment
had thus far failed and were offered a Phase I study. /d. Thirty-six subjects had recurrent
ovarian cancer and were offered a Phase II trial. /d. Twenty eight subjects were infected
with the HIV virus and were offered participation in a Phase III clinical trial. /d. Finally, 54
subjects were healthy volunteers who were enrolled in positron emission tomography
studies. See id. at 261-62.
While the ability of patients to remember information associated with their clinical
trials generally decreased as the severity of their illness increased, there were several
exceptions to this finding. /d. at 264. Immediate retention of information regarding clinical
trial procedures increased as the severity of illness increased. /d. In addition, Phase I and II
subjects showed the best long-term retention, while Phase III participants and healthy
volunteers retained the least on a long-term basis. /d. Finally, retention of information about
alternative therapies was the same among the three groups of sick subjects. /d.
See also Cassileth, supra note 92, at 898 (noting that "(b]edridden patients gave
significantly fewer correct responses to each item on the recall test [concerning
chemotherapy, radiation therapy, or surgery, to which they had consented the previous day]
than did ambulatory patients").
105
Addicott, supra note 103, at 502-03; Hewlett, supra note 103, at 233.
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RECOMMENDATIONS

A. IRBs
It is clear that many IRBs inadequately perform their oversight
functions. Their deficient performance, however, does not stem from
deliberate misconduct or indifference towards the welfare of human
subjects, but rather, from inadequate resources, unmanageable workloads,
and, in some cases, insufficient expertise. 106 Alleviating these problems is
essential to enhancing protection for clinical trial participants.
An effective means of improving the functioning of IRBs would be the
addition of more full-time, paid, professionals to their staffs. The size of
the professional staff would vary in accordance with the workloads of the
IRBs. The professional staff members should be charged with the review
of all protocols that are submitted for initial approval, amendment, and
continuing review to the IRB. One or two members of the IRB with
relevant medical expertise should also read each protocol and provide
comments to the staff. 107 The professional staff should then provide
written reports to the full IRB membership, summarizing the protocol and
their recommendations. The IRB volunteers would be responsible for
reading the reports, asking follow-up questions, and voting on whether to
approve the protocol.
Under this system, each IRB member will not be required to read every
page of every protocol, many of which are quite voluminous, and therefore
IRB duties will become less burdensome. The system will also expedite the
review process so that investigators will not have to wait several months
for approval of their submitted proposals. Finally, professional staffs
would assure that each protocol actually receives a thorough and
systematic initial review and continued monitoring, which many
commentators have suggested does not always occur when these tasks are
left exclusively in the hands of well-meaning, but overworked
volunteers. 108
Additional funding would obviously be needed to support the hiring of
adequate professional staffs. To obtain the necessary economic support,
IRBs could charge commercial research sponsors fot review of their
protocols. Similarly, if the research is sponsored by a governmental entity,
the sponsor could be required to add a fixed sum or a small percentage to

106

See Malinowski, supra note 7, at 63; Fleetwood, supra note 84, at 111.
Thus, a protocol relating to cancer treatment would be reviewed by professional
staff members and .by one or more oncologists, and a protocol relating to therapy for heart
disease would be reviewed by one or more cardiologists in addition to the professional staff.
108
See discussion supra Part liLA.
107
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its grant in order to support IRB activities. 109 Nothing in the federal
regulations prohibits the imposition of such charges.
B. Informed Consent Procedures
Professor Jay. Katz of Yale Law School has warned that obtaining true
informed consent is an "inordinately difficult task." 110 He suggests that
researchers must disclose to study participants at least the following data:
(1) that the subjects are not only patients and, to the extent
to which they are patients, that their therapeutic interests,
even if not incidental, will be subordinated to scientific
interests; (2) that it is problematic and indeterminate
whether their welfare will be better served by placing their
medical fate in the hands of a physician rather than an
investigator; (3) that in opting for the care of a physician
they may be better or worse off and for such and such
reasons; (4) that clinical research will allow doctors to
penetrate the mysteries of medicine's uncertainties about
which treatments are best, dangerous, or ineffective; (5)
that clinical research may possibly be in the patient's
immediate best interest, perhaps promise benefits in the
future, or provide no benefit, particularly if the patient is
assigned to a control (placebo) arm of a study; (6) that
research is governed by a research protocol and a research
question and, therefore, his or her interests and needs will
yield to the claims of science; and (7) that physicianinvestigators will respect whatever decision the subject
ultimately makes. 111

To these I would add a few other suggestions. Much of the general
infonnation discussed by Professor Katz should be included in a video
shown at the beginning of the informed consent process. The video should
clearly explain the difference between research and therapy and describe to
subjects their obligation to provide meaningful consent. In this television
age, people often find audio-visual aids to be an accessible and effective
communication tool that is an essential supplement to written materials and
verbal presentations. Educational videos have been successfully used by
many doctors. In 1998, for example, the Foundation for Informed Medical
Decision Making produced a video entitled "The PSA Decision: What
109

For a detailed discussion of recommendations for the enhancement of IRB
effectiveness see Sharona Hoffman, Continued Concern: Human Subject Protection, the
Institutional Review Board, and Continuing Review, 68 TENN. L. REv. 725 (2001).
110
Katz, supra note 92, at 34.
111

/d.
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You Need to Know," which was intended to assist asymptomatic men over
50 in deciding whether to undergo prostate-specific antigen (PSA) tests. 112
The informed consent process should also rndude a .thorough
discussion between the potential subject and the investigator or a research
nurse, in which all the details of the trial are verbally explained. 113
Potential participants should then be quizzed to ascertain that they fully
understand the information they have received and to determine whether
they are able to articulate answers to specific questions. 114 The inform~d
consent process should continue until the investigator is satisfied that the
potential subject understands all necessary information. 115 Those who fail
to demonstrate a satisfactory level of comprehension after the· investigator
or a nurse has invested a reasonable amount of time and effort in the
informed consent process should not be enrolled as human subjects. 116
To facilitate reading comprehension, informed consent documents
should be written in simple lan~uage that can be understood by people with
an eighth grade reading level. 1 7 If at all possible, IRBs should include at
least one member with expertise in reading comprehension or elementary
education who could scrutinize informed consent forms to determine their
readability and recommend simplifications where appropriate. 118
112

THE PSA DECISION: WHAT You NEED To KNow, (The Foundation for Informed
Medical Decision Making (1998)).
113
See Riecken & Ravich, supra note 93. The article discusses a survey of 188 male
veteran patients who were human subjects in research projects in four VA hospitals. Thirty
seven principal investigators were also surveyed. Of investigators who were personally .
responsible for explaining the study to patients, approximately half reported that they spent
less than 15 minutes obtaining informed consent from patients, and a third stated that they
spent between 15 and 30 minutes. Riecken & Ravich, supra note 93, at 345. Twenty-eight
percent of research participants did not realize that they were enrolled in a clinical trial, and
they were concentrated in the studies in which the investigators invested the shortest
periods of time in the consent process. Riecken & Ravich, supra note 93, at 345. Only one
investigator had no unaware participants. He had given e.ach potential subject a short
examination after providing an explanation of the study. If the patient did not pass, the trial
was described again. Riecken & Ravich, supra note 93, at 347.
114
.
See Katz, supra note 92, at 36-37.
115
See Katz, supra note 92, at 36.
116
See Riecken & Ravich, supra note at 93.
117
Grossman., supra note 94, at 2212. The authors found that the typical consent
form that describes a clinical oncology protocol is "too complex to be read by most patients
and their families." The average person reads at approximately an eighth grade reading
level, and the mean grade level required for comprehension of the forms that were studied
was between 11.1 and 14.1, depending on the index used. See id.
118
21 C.F.R. §56.108(c); 45 C.F.R. § 46.108(b). IRBs must include at least one
community representative whose primary concerns are nonscientific. 21 C.F.R. §56.108(c);
(continued)
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C. Storage Of Blood And Tissue Samples For Future Genetic Testing
Many clinical trials include blood tests or tissue biopsies. Once testing
has been completed for purposes of the study, investigators often wish to
store the blood or tissue samples for purposes of future genetic testing. 119
It is difficult to obtain meaningful informed consent for unknown future
studies because researchers cannot accurately describe the research that
will be conducted or the data that will be sought.
In addition, genetic testing raises important concerns about privacy and
potential discrimination. 120 If confidentiality is not properly maintained
and genetic data about an individual is disclosed to third parties, such as
employers and insurers, theindividual might suffer discrimination. 121 For
example, genetic testing might reveal that a person is susceptible to a
particular cancer, leading employers who obtain these test results to
decline to hire her and insurers to deny her coverage because of anticipated
costs that will be generated by her likely poor health status in the future. 122
Consequently, it is important that careful efforts be made to obtain
informed consent for the storage of blood and tissue samples for purposes
of future genetic testing. 123 Consent for tissue storage should be separate
from consent for the underlying clinical trial, and thus, the subject should
receive two consent documents and be required to provide two consent
signatures for studies that contemplate future genetic testing. Subjects
must be alerted to the fact that the issue of tissue storage is different from
the issue of participation in the underlying trial and that it requires a
separate decision-making process.
The consent form should address how confidentiality will be
safeguarded and inform subjects about whether their samples will be deidentified. It should also disclose to participants that they will not
personally benefit from future genetic testing in that researchers will not

45 C.F.R. § 46.l08(b). The regulations do not specify what the community representative's
nonscientific expertise should be. See id. In light of contemporary concerns about the
readability of informed consent documents, however, IRBs would be wise to choose a
layperson whose field of specialty is reading comprehension or elementary education.
119
Goerge J. Annas, The Limits ofState Laws to Protect Genetic Information, 345 N.
ENGL. J. MED. 385, 387 (2001).
120
!d.
121

!d.; See also Mark A. Rothstein & Sharona Hoffinan, Genetic Testing, Genetic
Medicine, and Managed Care, 34 WAKE FOREST L. REv. 849, 865-71.
122
Annas, supra note 120.
123
One commentator states that in reality what is being obtained is a waiver of
informed consent, because the subject generally agrees not to be notified about or consent
to future testing. Interview with Pilar Ossorio, Assistant Professor of Law, University of
Wisconsin Law School (Nov. 30, 2001).
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contact subjects or their doctors to provide test results. Furthermore,
subjects should be informed that the research sponsor might profit from
future research if it develops a new drug or therapy that is successfully
marketed but that the individuals whose samples were utilized will not
receive a share of the sponsor's earnings.
Finally, the consent form should provide subjects with choices as to
the type of research to be conducted using their samples. For example,
participants in a clinical trial relating to preast cancer who agree to storage
of their samples could be asked to select from among the following: 1) I
agree to have my sample used for future genetic testing related to breast
cancer; 2) I agree to have my sample used for future genetic testing related
to diseases other than breast cancer; and 3) I agree to have my sample
stored but wish the investigator to contact me for permission before any
testing is conducted in the future. If subjects read, think about, and
respond to specific questions, investigators can be reassured that
participants have understood the choices they were required to make and
have provided meaningful consent.

VI. CONCLUSION
Enhancement of protections for human subjects will undoubtedly
impose added costs for clinical research. Increasing 1he number of IRB
professionals will require funcling by private and. governinental research
sponsors. 124 A conscientious effort to obtain meaningful consent may
delay recruitment of subjects and completion of research. 125 A valid
informed consent process mar, require several hours or even repeated
conversations over a few days~ 26 Furthermore, if patients fully understand
all components and risks of a protocol, they may more often refuse to
enroll, making some studies difficult or, in rare cases, impossible to
conduct. 127 These negative consequences, however, are outweighed by the
advantages of enhancing the integrity of biomedical research, bolstering
human subject protection, and reducing the likelihood of liability
associated with clinical studies.
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See Katz, supra note 92; at 38.
Katz, supra note 92, at 36.
126
Riecken & Ravich, supra note 93, at 345-47~
127
See Gina Kolato & Kurt Eichenwald, Hope for Sale: A Special Report; Business
Thrives on Unproven Care, Leaving Science Behind, N.Y. TIMES, Oct. 3, 1999, at Al
(discussing the difficulties faced by some investigators who wish to recruit patients to
participate in clinical trials involving treatments for serious illnesses such as cancer, heart
failure, and Parkinson's disease). /d.
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